Featuring Professor David Thomas, Chief Science and Strategy Officer, at Omico and Christine Cockburn, Chief Executive Officer at Rare Cancers Australia.

Future Prospects – What Lies Ahead? This episode explores the importance of genomic profiling and precision oncology, highlighting what’s needed to expand its use. The episode examines potential advancements over the next 5 to 10 years and discusses key hopes and priorities for the future.